Dopamine agonist therapy in prolactinomas: When can treatment be discontinued?

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 7, 2009, Pages 2247-2249

  Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PROLACTIN;

CAVERNOUS SINUS; DRUG WITHDRAWAL; EDITORIAL; HUMAN; HYPERPROLACTINEMIA; OPTIC CHIASM; PARKINSON DISEASE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RECURRENT DISEASE; RISK; TUMOR GROWTH; TUMOR VOLUME; VALVULAR HEART DISEASE;

EID: 67650221390     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0999     Document Type: Editorial

References (22)

1. Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A 1989 The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412-418
2. Jeffcoate WJ, Pound N, Sturrock NDC, Lambourne J 2003 Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 45:299-303
3. Zá rate A, Canales ES, Cano C, Pilonieta CJ 1983 Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh) 104:139-142
4. Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB 1984 Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas: studies with high-definition computerised tomography. Lancet 2:187-192
5. Moriondo P, Travaglini P, Nissim M, Conti A, Faglia G 1985 Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60:764-772
6. Wang C, Lam KS, Ma JT, Chan T, Liu MY, Yeung RT 1987 Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol (Oxf) 27:363-371
7. van 't Verlaat JW, Croughs RJ 1991 Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34:175-178
8. Passos VQ, Souza JJ, Musolino NR, Bronstein MD 2002 Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87:3578-3582
9. Cannavò S, Curtò L, Squadrito S, Almoto B, Vieni A, Trimarchi F 1999 Cabergoline: a first-choice treatment in patients with previously untreated prolactinsecreting pituitary adenoma. J Endocrinol Invest 22:354-359
10. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G 2003 Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023-2033
11. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G 2007 Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67:426-433
12. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS 2005 Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63:26-31
13. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A 2006 Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265-273
14. Kharlip J, Salvatori R, Yenokyan G, Wand GS 2009 Recurrence of Hyperprolactinemia following Withdrawal of Long-Term Cabergoline Therapy. J Clin Endocrinol Metab 94:2428-2436
15. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331:904-909
16. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA, Schoenfelder JR, Klibanski A 1996 Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338-2343
17. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29-38
18. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46
19. Devin JK, Lakhani VT, Byrd 3rd BF, Blevins Jr LS 2008 Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 14:672-677
20. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A 2008 Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1-5
21. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G 2008 Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 93:3777-3784
22. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E 2008 Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 31:1119-1123